Product Description
AMG 378 is a small molecule being investigated for the treatment of ulcerative colitis. (Sourced from: https://www.amgenpipeline.com/)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Amgen
Company Location: Western America
Company Founding Year: 1980
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06910709 |
NCT06910709 | P1 |
Terminated |
Healthy Volunteers |
2025-12-02 |
88% |
2026-04-03 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
Recent News Events
Date |
Type |
Title |
|---|